Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aspect Medical Systems

This article was originally published in The Gray Sheet

Executive Summary

Initial public offering of up to $53.5 mil. in common stock is outlined in a preliminary prospectus filed with the Securities and Exchange Commission. The number of shares to be offered and price per share are not yet determined. Proceeds are tabbed for sales and marketing, R&D, a "sales-type" lease program, working capital and "other corporate purposes," the firm states.The Natick, Massachusetts company makes anesthesia monitoring systems for use as a direct measure of anesthetic effect on the brain using its bispectral index technology - which was originally cleared by FDA in 1996 as a means to improve clinical outcomes and lower the cost of anesthesia care. In February, Aspect received 510(k) clearance to market the BIS as part of its A-2000 monitor, a next-generation version of its A-1050 monitor. An Aspect BIS module is also available for use with any of the monitors in Spacelabs Medical's Patient Care Monitoring System product line under an OEM agreement ("The Gray Sheet" March 16, p. 6). Aspect achieved sales of $3.1 mil. in 1997 (up 120%) and recorded a net loss of $9.9 mil. for the period. BT Alex. Brown, Merrill Lynch and Piper Jaffray are underwriters for the offering

Latest Headlines
See All
UsernamePublicRestriction

Register

MT010357

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel